The synthesis of fucosyl GM 1 pentenyl glycoside 1b, and its conjugation to carrier protein KLH to give 1c is related. Bioconjugation of 1b was realized using the pendant olefin contained in the reducing end n -pentenyl glycoside (NPG). The key step of the endeavor is a stereospecific [3 + 3] coupling reaction using our sulfonamido glycosidation protocol (see 23 + 12 → 15 ). Pre-installation of the NPG was required for an optimal [3 + 3] coupling yield and to allow for smooth global deprotection. The synthesis and subsequent immunocharacterization served to confirm the assigned structure of the natural tumor antigen. Fully synthetic conjugate 1c advances our program toward the goal of using a synthetic vaccine containing fucosyl GM 1 as a potential target for immune attack against small cell lung carcinoma.
No takes yet. Share an insight, caveat, or question.
Allen et al. (1999) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: